In vivo effects of pardoprunox (SLV308), a partial D2/D3 receptor and 5-HT1A receptor agonist, on rat dopamine and serotonin neuronal activity

Third Generation Antipsychotic Drugs: Partial Agonism or Receptor Functional Selectivity?

(2010) Richard Mailman et al.   CURRENT PHARMACEUTICAL DESIGN

Double-blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson's disease

(2010) Juliana Bronzova et al.   MOVEMENT DISORDERS

Pardoprunox reverses motor deficits but induces only mild dyskinesia in MPTP-treated common marmosets

(2010) Louisa Clare Johnston et al.   MOVEMENT DISORDERS

Unilateral lesion of the nigrostriatal pathway induces an increase of neuronal firing of the midbrain raphe nuclei 5-HT neurons and a decrease of their response to 5-HT1A receptor stimulation in the rat

(2009) S. Wang et al.   NEUROSCIENCE

Bifeprunox and aripiprazole suppress in vivo VTA dopaminergic neuronal activity via D2 and not D3 dopamine autoreceptor activation

(2009) Adeline Etievant et al.   NEUROSCIENCE LETTERS

Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of l-Dopa in parkinsonian monkeys

(2009) Laurent Grégoire et al.   PARKINSONISM & RELATED DISORDERS

Antiparkinsonian Medication and Pathological Gambling

(2008) Malcolm Lader   CNS DRUGS

Effects of bifeprunox and aripiprazole on rat serotonin and dopamine neuronal activity and anxiolytic behaviour

(2008) L Dahan et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Non-dopaminergic treatments in development for Parkinson's disease

(2008) Susan H Fox et al.   LANCET NEUROLOGY